Articles tagged with “biotech-ipo”

Kailera Therapeutics IPO: GLP-1 Obesity Pipeline Analysis

Explore Kailera Therapeutics' $625M IPO and GLP-1 obesity pipeline. This analysis covers clinical data, dual agonists, and the 2026 biotech market reopening.

65 min read

4/20/2026

kailera therapeutics glp-1 agonists obesity pipeline biotech ipo dual agonists clinical trials biopharma finance